By Dr. Amit Tandon
Chief of Interventional Pulmonology, Pioneer Health
If there is one truth I wish every patient, primary care physician, and health system fully understood about lung cancer, it is this: When we diagnose the disease matters more than almost anything else.
Not a new chemotherapy. Not a breakthrough drug. Not even the most advanced surgical technique. Speed and early detection are the differences between cure and palliation, which means we are left trying to improve the patient’s quality of life without the ability to cure the underlying disease.
This is true across the medical spectrum, but it is a critical element in interventional pulmonology. Lung cancer outcomes are starkly stage-dependent.
When diagnosed at Stage I, five-year survival exceeds 90 percent. By the time the disease reaches late Stage III or Stage IV, five-year survival drops to 20 percent or less. What is often overlooked is how quickly that window closes.
I routinely see cases where a delay of two to three months, often caused by slow referrals, uncertainty about next steps, or lack of access to diagnostic expertise, shifts a patient from a curative pathway to a palliative one.
In that short time span, an operable cancer can become inoperable.
That is not a failure of medicine.
It is a failure of systems.
Why Early Detection Has Historically Been So Hard
For decades, diagnosing lung cancer early was limited by technology. Small nodules deep in the lung were difficult, often impossible, to reach safely. The diagnostic yield was, quite literally, a coin flip.
We just didn’t have the tools to know enough early enough in the process.
As a result, many patients were diagnosed only after symptoms appeared, when the disease was already advanced. Others underwent invasive surgical biopsies that required hospital stays, chest tubes, and carried significant risks, just to establish a diagnosis.
This reality conditioned both physicians and patients to accept delay as inevitable.
It no longer is.
What Has Changed: Precision, Minimally Invasive Diagnosis
Today, robotic bronchoscopy has fundamentally changed what is possible.
Using advanced robotic navigation, we can biopsy lung nodules as small as six millimeters. That’s roughly the size of a number-two pencil eraser. And we can do it with 85 to 90 percent diagnostic accuracy.
A decade ago, that would have been unthinkable.
Today’s procedures are:
Minimally invasive
Performed as same-day outpatient procedures
Completed in about an hour
Associated with complication rates under 1–2 percent
Instead of a three-day hospital stay, patients go home within an hour. Instead of waiting months for answers, they can move quickly to surgery, oncology, or radiation, while the option to cure is still on the table.
Early detection is no longer theoretical. It is operational.
Speed Is the Hidden Survival Variable
Technology alone is not enough. Speed is the true differentiator.
Nationally, the average time from lung cancer suspicion to diagnosis is approximately 56 days. In many systems, it stretches to three months or longer. That’s simply too long.
In our model, we have reduced that timeline to 21 days, and often much less.
How?
Direct physician-to-physician communication
Immediate triage of referrals
Same-day or next-day clinic access when needed
Constant coordination between pulmonology, surgery, oncology, radiology, and pathology
Every referring provider has direct access to my team and me. If they have a concern, they text or call, and we act.
That speed is not a convenience.
It is a clinical intervention.
Collaboration Multiplies Outcomes
Early diagnosis does not end with a biopsy.
Every other week, we convene a multidisciplinary tumor board that brings together pulmonology, thoracic surgery, medical oncology, radiation oncology, radiology, and referring physicians from across Florida. Thirty to forty specialists may be present on a single call.
Each patient benefits from collective expertise, not sequential handoffs.
This model ensures that once a diagnosis is made, the next step is never unclear or delayed.
Lung cancer remains the leading cause of cancer death, in part because it is under-screened and under-diagnosed early. Many primary care physicians hesitate to order low-dose CT scans because they are unsure where to send patients next.
My message is simple: Send them to us. We will take it from there.
Early detection only works if physicians trust that a clear, efficient pathway exists after screening.
Our first objective is always to cure.
When we diagnose cancer early, we give patients the best possible chance, not just to live longer, but to live fully. Even when early detection is no longer an option, we still have tools to restore breathing, dignity, and quality of life. But those interventions should be the exception, not the rule.
The future of lung cancer care is not just about better drugs. It is about finding cancer sooner, acting faster, and removing every unnecessary delay between suspicion and treatment.
Early detection is not one lever among many. It is the lever.
About the Author
Amit Tandon, M.D., is a nationally recognized interventional pulmonologist and Master Surgeon in Robotic-Assisted Bronchoscopy (Surgical Review Corporation) who currently serves as Chief of Interventional Pulmonology at Pioneer Critical Care. He specializes in advanced diagnostic and therapeutic bronchoscopy, pleural diseases, and treating conditions like pulmonary heart disease and asthma. He has completed over 500 Ion Robotic Bronchoscopy procedures.